US Bancorp DE Raises Stock Position in Bruker Co. (NASDAQ:BRKR)

US Bancorp DE increased its stake in Bruker Co. (NASDAQ:BRKR) by 2.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 12,700 shares of the medical research company’s stock after acquiring an additional 260 shares during the quarter. US Bancorp DE’s holdings in Bruker were worth $877,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. TD Asset Management Inc raised its position in shares of Bruker by 7.4% in the first quarter. TD Asset Management Inc now owns 1,788,763 shares of the medical research company’s stock valued at $168,036,000 after buying an additional 123,984 shares during the last quarter. Atria Investments Inc acquired a new stake in shares of Bruker in the first quarter valued at about $1,142,000. Point72 Asset Management L.P. acquired a new stake in shares of Bruker in the second quarter valued at about $36,472,000. Epoch Investment Partners Inc. raised its position in shares of Bruker by 15.2% in the first quarter. Epoch Investment Partners Inc. now owns 466,865 shares of the medical research company’s stock valued at $43,857,000 after buying an additional 61,429 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its position in shares of Bruker by 1,694.4% in the second quarter. Assenagon Asset Management S.A. now owns 202,733 shares of the medical research company’s stock valued at $12,936,000 after buying an additional 191,435 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Price Performance

Shares of BRKR opened at $57.73 on Friday. Bruker Co. has a 1-year low of $54.55 and a 1-year high of $94.86. The stock has a market cap of $8.74 billion, a PE ratio of 27.75, a P/E/G ratio of 2.83 and a beta of 1.20. The firm has a 50-day simple moving average of $63.64 and a two-hundred day simple moving average of $66.21. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.75.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a net margin of 9.41% and a return on equity of 21.52%. The company had revenue of $864.40 million for the quarter, compared to analyst estimates of $866.46 million. During the same quarter in the prior year, the business earned $0.74 earnings per share. Bruker’s revenue was up 16.4% on a year-over-year basis. As a group, analysts forecast that Bruker Co. will post 2.39 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. TD Cowen reduced their target price on shares of Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research report on Wednesday. Wolfe Research cut shares of Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. Barclays cut their price objective on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research report on Wednesday. Wells Fargo & Company cut their price objective on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, Citigroup cut their price objective on shares of Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $79.36.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.